JERUSALEM, Aug. 15 (Xinhua) -- A coronavirus vaccine developed by the Israel Institute for Biological Research (IIBR) and the U.S.-based company NRx Pharmaceuticals was starting new second phase trials in Georgia, an Israeli government spokesperson said Sunday.
During the weekend, a shipment of 1,125 vaccine vials have been delivered to Georgia, where the second phase of clinical trials for the BriLife coronavirus vaccine will be expanded later, the Israeli Defense Ministry said in a statement.
The clinical trials in Georgia will take place simultaneously with the second phase of clinical trials in Israel, the ministry said.
The IIBR and NRx signed an agreement in July to jointly complete the clinical trials and commercialize the potential COVID-19 vaccine.
